T (any), N (any), M1 5-7
5-Fluorouracil (5-FU), an antimetabolite, acts by inhibiting DNA synthesis. Until mid-90s 5-FU with its various schedule and biomodulated forms have been used as adjuvant therapy, and in metastatic CRC with prolongation of medium survival from approximately six months (without treatment) to about 11 months [14] [15] [16] [17] [18] . Biochemical modulation of 5-FU and/or administration as continuous infusion are achievements of the 1980s and have resulted in increased response rate and prolonged progression free survival (PFS), while the influence on overall survival (OS) has been limited [19] [20] [21] [22] .
Despite controversies about efficacy of 5-FU in adjuvant setting, recent meta-analysis demonstrated probability of remaining free of tumour recurrence after five years in stage-III disease from 42 percent to 58 percent and likelihood of five year overall survival from 51 percent to 64 percent. 23 Role of adjuvant therapy in stage-II disease is still controversial and is recommended only in high risk cases -tumour adhesion to adjacent organ, bowel perforation or obstruction [24] [25] [26] . Different regimens of 5-FU varies in doses and schedule. Mayo clinic regimen uses bolus administration of 5-FU and Leucovorin whereas de Gramont regimen utilizes continuous infusion of 5-FU. Though absolute gain in efficacy of one regimen over the other of these gamut of schedules has not been observed, toxicity profile varies considerably. de Gramonts one produces more hand-foot syndrome but less gastrointestinal and haematologic toxicity compared to bolus schedules, and is claimed to be moderately more effective than a rapid bolus approach 22 . Single agent activity of Irinotecan 15, 27, 28 and Oxaliplatin 29 in metastatic CRC led to their use in combination with 5-FU/LV for treatment of patients in advanced disease as well as in adjuvant setting.
Oral fluorinated pyrimidines, UFT, Eniluracil, S-1 and Capecitabine (Xeloda) have the advantage of avoiding hospital visits and admissions for administration. UFT, Eniluracil and S-1 have not been very popular but Capecitabine, a pro-drug of 5-FU, which is tumour activated, has shown promising response, at least as good as 5-FU, but impact on median overall survival is not significant. 13 In fact, it has replaced 5-FU as the backbone of many combinations in recent past because of its favorable safety profile, convenience and cost-effectiveness. Capecitabine's unique mechanism of tumour activation results in the generation of 5-FU preferentially in tumor tissues, minimizing systemic exposure to this drug 30 , Moreover, its chemical structure prevents direct release of 5-FU in gastrointestinal tract and its associated toxicities. Capecitabine mono-therapy is an established treatment option for patients with anthracycline and taxane pretreated metastatic breast cancer 31, 32 and is active in patients with metastatic CRC 11, 13, 33 . Two large phase-III trials have demonstrated that, as first line therapy for metastatic CRC, Capecitabine achieves significantly superior response rates, equivalent time to disease progression and equivalent survival compared with 5-FU/ LV 13, 33, 34 . Drugs approved by FDA for treatment of CRC is shown in Table- II. 39 . This regimen had already doubled the response rates and prolonged progression free survival among patients with metastatic CRC 38 and is superior to IFL 40 . Furthermore, studies with Oxaliplatin plus 5-FU / LV have indicated that a highly active first line chemotherapy regimen may permit, in a small sub group of initially unresectable metastatic CRC patients, a radical approach to metastases after response to chemotherapy, and that approximately 30-40% of operated patients will survive without evidence of disease for greater than five years. 41, 42 Therefore, these data indicate that, in metastatic CRC, a more active first line treatment can be more effective, and a meta-analysis of 15 randomized trials of first line treatment with standard bolus intravenous fluoropyrimidines versus experimental treatments (5-FU plus LV, 5-FU plus Methotrexate, 5-FU -CI) also support the relationship between tumour response to first line chemotherapy and survival 40 . The GERCOR study 43 compared FOLFIRI and FOLFOX in sequential order, FOLFIRI followed by FOLFOX vs. FOLFOX followed by FOLFIRI and found median survival of 20.6 months vs. 21.5 months, the highest survival times reported up to now in any randomized study of metastatic CRC. This study suggests that exposure of metastatic CRC patients to all these most active agents 5 FU/LV, Irinotecan and Oxaliplatin, is associated with promising survival which is also supported by study of Goldberg et al 40 . Another recent phase-III trial demonstrated that survival in MCRC is correlated with the proportion of patients who received all the three active drugs in the course of their disease, but not with the proportion of patients who received any second line therapy 44 . That is why upfront administration of all these three drugs in 100% patients, if feasible and tolerable, should be attempted. Moreover, no data is available supporting the hypothesis that patients progressing rapidly on a two drug combination (FOLFOX or FOLFIRI) will respond to a triplet (FOLFOXIRI) or any currently available chemotherapy. The initial FOLFOXIRI 45 and its better tolerable version 46 have demonstrated maximum efficacy of median progression free survival of 10.4 and 10.8 months and median overall survival of 26.5 months and 28.4 months respectively.
Table-II

Glossary of treatments for colorectal cancer
Targeted therapy:
Angiogenesis plays central role in growth and spread of many solid tumours. Attempt to inhibit these factors constitutes rational approach in causing tumour shrinkage and prevention of its spread. Of the different factors VEGF (vascular endothelial growth factor) and EGFR (epithelial growth factor receptor) received much attention. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody against VEGF, was tried in combination with chemotherapeutic agents in trials [47] [48] [49] . The study by Hurwitz and colleagues 44 , who added Bevacizumab with IFL, revealed an impressive, statistically significant increase in median overall survival and a 4.7 months prolongation in median overall survival (to 20.3 months vs 15.6 months with IFL and placebo). A recent study, adding Bevacizumab to FOLFOX as compared to FOLFOX alone, in patients who previously received Irinotecan based therapy, demonstrated a statistically significant prolongation in median survival 50 . Of late, Bevacizumab received FDA approval for treatment of advanced CRC patients with any Fluorouracil containing regimen. 51 Thalidomide, as an angiogenesis inhibitor, has been in use for multiple myeloma and other solid tumours. Recent evidence suggests its role in CRC along with chemotherapeutic agents. 52 Cetuximab (Erbitux), a monoclonal antibody against EGFR, is approved in USA for treatment of metastatic CRC. Saltz and colleagues studied combination of Cetuximab and Irinotecan in advanced CRC unresponsive to Irinotecan alone , and found radiological objective tumour regression in 19% of patients. 53 Study by Cunningham and colleagues confirmed the above experience who found 23% disease regression in patients who received Irinotecan and Cetuximab compared to 11% in those who received cetuximab alone. 54 The FDA approved drugs/ regimens are shown in Table- II and impact of these agents on median survival, particularly in advanced disease, over the last decade, is reflected in Table-III .
Future:
Last decade has witnessed profound improvement in chemotherapy of CRC after long plateau in survival curve. Many ongoing trials are attempting to achieve further gain in treatment outcome. Along with currently available reasonably effective agents, greater focus is now directed towards targeted therapy either alone or in combination with chemotherapeutic agents. ZD1839(Irresa), OSI-774(Tarceva), COX-2 inhibitors, farnesyltransferase inhibitors (e.g Zarnestra), to name only few, among the novel agents which are being incorporated in therapy, with hope of and aspiration to increase survival and relieve symptoms in advanced disease as well as early and locally advanced disease. 44 .
